Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012
about
Emerging Threats in Antifungal-Resistant Fungal PathogensAntifungal susceptibility testing: current role from the clinical laboratory perspectiveMicafungin: an evidence-based review of its place in therapyThe widely used ATB FUNGUS 3 automated readings in China and its misleading high MICs of Candida spp. to azoles: challenges for developing countries' clinical microbiology labsSynergistic Effect of Fluconazole and Calcium Channel Blockers against Resistant Candida albicansAge and Gender Affect the Composition of Fungal Population of the Human Gastrointestinal TractResistance Mechanisms and Clinical Features of Fluconazole-Nonsusceptible Candida tropicalis Isolates Compared with Fluconazole-Less-Susceptible IsolatesDrug resistance in eukaryotic microorganisms.Surveillance of the prevalence, antibiotic susceptibility, and genotypic characterization of invasive candidiasis in a teaching hospital in China between 2006 to 2011.Multicenter evaluation of the new Vitek 2 yeast susceptibility test using new CLSI clinical breakpoints for fluconazole.Regional data analysis of Candida non-albicans strains collected in United States medical sites over a 6-year period, 2006-2011.In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012.Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012).A multi-centric Study of Candida bloodstream infection in Lima-Callao, Peru: Species distribution, antifungal resistance and clinical outcomesCaspofungin-Non-Susceptible Candida orthopsilosis Isolated from Onychomycosis in Iran.Surveillance of Candida spp bloodstream infections: epidemiological trends and risk factors of death in two Mexican tertiary care hospitalsMultilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole.Epidemiology, species distribution and outcome of nosocomial Candida spp. bloodstream infection in ShanghaiCandidemia in the elderly: What does it change?Molecular epidemiology and azole resistance mechanism study of Candida guilliermondii from a Chinese surveillance system.Two missense mutations, E123Q and K151E, identified in the ERG11 allele of an azole-resistant isolate of Candida kefyr recovered from a stem cell transplant patient for acute myeloid leukemia.Antifungal susceptibilities of Candida isolates causing bloodstream infections at a medical center in Taiwan, 2009-2010ERG11 Gene Mutations and MDR1 Upregulation Confer Pan-Azole Resistance in Candida tropicalis Causing Disseminated Candidiasis in an Acute Lymphoblastic Leukemia Patient on Posaconazole Prophylaxis.Non-albicans Candida Infection: An Emerging ThreatAdvances in identification of clinical yeast isolates by use of matrix-assisted laser desorption ionization-time of flight mass spectrometry.Rapid antifungal susceptibility testing by matrix-assisted laser desorption ionization-time of flight mass spectrometry analysis.Susceptibility of Candida spp. isolated from blood cultures as evaluated using the M27-A3 and new M27-S4 approved breakpointsAntifungal susceptibilities of bloodstream isolates of Candida species from nine hospitals in Korea: application of new antifungal breakpoints and relationship to antifungal usage.Isolation of cholesterol-dependent, multidrug-resistant Candida glabrata strains from blood cultures of a candidemia patient in Kuwait.Antifungal activity of naphthoquinoidal compounds in vitro against fluconazole-resistant strains of different Candida species: a special emphasis on mechanisms of action on Candida tropicalis.Antifungal pharmacokinetics and pharmacodynamicsDetection of triazole resistance among Candida species by matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS).Ibuprofen potentiates the in vivo antifungal activity of fluconazole against Candida albicans murine infectionAntifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital.Retrospective analysis of mortality and Candida isolates of 75 patients with candidemia: a single hospital experience.Quantitative Microplate-Based Growth Assay for Determination of Antifungal Susceptibility of Histoplasma capsulatum Yeasts.Factors related to outcome of bloodstream infections due to Candida parapsilosis complexThe Candida albicans ATO Gene Family Promotes Neutralization of the Macrophage PhagolysosomeIdentification and Antifungal Susceptibility Profiles of Candida nivariensis and Candida bracarensis in a Multi-Center Chinese Collection of Yeasts.Molecular Characterization of Candida africana in Genital Specimens in Shanghai, China
P2860
Q26750816-5F824004-43A4-40C3-BAC6-D1DA0CF32456Q26862478-A8176DD6-BA61-459D-85D4-DFD0CE2154C5Q27014780-6685D96C-FF47-4A99-AB4F-45F7650668FAQ28542429-3C048D6B-099D-475A-BABB-BF22B69E273AQ28550850-C48E985B-3A20-49F4-8E21-71592C16CED4Q28831500-E61EA8D5-2EE4-4436-9E56-97BDF0AC8CEAQ28833536-43AEB15E-99DD-48A7-95AB-A237FE568A50Q30248243-A37F8149-56D9-47AA-A593-CCFBB00E84A9Q30658189-5F81F25C-A673-4D01-8C92-1495C1CF42A4Q30797685-79D1A5DA-DD97-4281-BDFC-0F44185F0D84Q30826889-93543C81-DC83-4AE3-A263-E845F4D3E7E1Q30902025-DC89B50D-04D0-4FC5-9392-462C2B8773E7Q30938136-805F8774-0F3F-4297-874A-F2DACCAADAEDQ33574303-9692CAB7-AC17-462A-8542-80115F2690DEQ33596063-C47CCEC1-85B1-4416-A3D9-F32C699D53ADQ33618418-0E6F5591-9A8D-4B53-8409-EAB1C1AF3DC0Q33622915-D430B302-D0AB-4481-8176-60CF8AD5CEC8Q33661367-C1A351EB-CBAF-4FC0-9181-F59981BF760FQ33663448-AF3FED2D-1B56-479A-BE03-D77C98C76E4CQ33680814-5940484F-9A74-4B78-AFC1-1F086197385AQ33736888-4AC29587-544A-43DF-8949-ECA6006C51CAQ33798413-8EE8987B-79E0-4365-A936-05862FB00788Q33843670-D9B34867-F378-4545-8E4E-8112A269F4ACQ34488096-C5528E7B-CE22-451B-A8B0-2AF8F6968654Q34593760-2DBADCB5-7C7E-4ACB-81AF-758805B6C5A7Q34793588-3318BF39-AB7B-4C90-B15F-91358EDE8F47Q34977249-B9316D0E-47CA-481F-8794-9EDD9C15B222Q35112435-B26626AC-3A17-4968-A846-040BE80C0B47Q35142438-B1F1564E-7F16-4FBA-B28B-7EBABDB8B5FFQ35166731-C5479743-FB92-4C2D-9F49-59C7335763CDQ35663841-21E9BDDC-04E8-4A9A-B316-9CAB2C219250Q35688413-8AB78D67-7DD7-42F0-8F1E-1CEA97713F8BQ35746053-4F8695A0-8C92-40BE-A78D-E3C32567DF36Q35746090-6017305C-9C4F-4B32-80FC-89D4B44D30ACQ35848669-8A379121-AB7D-47F2-BBEF-F146448BEE15Q36066802-0DB1B642-85C3-40BC-B5CA-B2827A125DBCQ36099691-FB8282AE-0208-4E9E-B527-8DB81F1981C0Q36138048-F162938A-CA2A-4346-A7FE-33F970F84400Q36268445-3835C76E-BFC3-463D-B9FD-CED876E847BFQ36343085-3731370B-2618-4926-8C73-D694F8FDFA7D
P2860
Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Progress in antifungal suscept ...... dilution methods, 2010 to 2012
@ast
Progress in antifungal suscept ...... dilution methods, 2010 to 2012
@en
type
label
Progress in antifungal suscept ...... dilution methods, 2010 to 2012
@ast
Progress in antifungal suscept ...... dilution methods, 2010 to 2012
@en
prefLabel
Progress in antifungal suscept ...... dilution methods, 2010 to 2012
@ast
Progress in antifungal suscept ...... dilution methods, 2010 to 2012
@en
P2860
P356
P1476
Progress in antifungal suscept ...... dilution methods, 2010 to 2012
@en
P2093
D J Diekema
M A Pfaller
P2860
P304
P356
10.1128/JCM.00937-12
P407
P577
2012-06-27T00:00:00Z